Interleukin-2 Receptor Targeted Therapy of Ocular Disease of HTLV-1-associated Adult T-cell Leukemia

Theresa A. LarsonNational Eye Institute, National Institutes of Health, Bethesda, Maryland, USA

, MD,

Mengjun HuNational Eye Institute, National Institutes of Health, Bethesda, Maryland, USA

, BS,

John E. JanikMetabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA

, MD,

Robert B. NussenblattNational Eye Institute, National Institutes of Health, Bethesda, Maryland, USA

, MD, MPH,

John C. MorrisMetabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA

, MD &

H. Nida SenNational Eye Institute, National Institutes of Health, Bethesda, Maryland, USACorrespondence[email protected]

, MD, MHSc

REFERENCES

Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer. 2007:7(4):270–280.
PubMed Web of Science ®Google Scholar
Buggage RR. Ocular manifestations of human T-cell lymphotropic virus type 1 infection. Curr Opin Ophthalmol. 2003:14(6):420–425.
PubMedGoogle Scholar
Waldmann TA. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol. 2007:27(1):1–18.
PubMed Web of Science ®Google Scholar
Papaliodis GN, Chu D, Foster CS. Treatment of ocular inflammatory disorders
Google Scholar
with daclizumab. Ophthalmology. 2003 Apr;110(4):786–789.
PubMed Web of Science ®Google Scholar
Manoukian G, Hagemeister F. Denileukin diftitox: a novel immunotoxin. Expert Opin Biol Ther. 2009:9(11):1445–1451.
PubMed Web of Science ®Google Scholar
Yeh S, Wroblewski K, Buggage R, et al. High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun. 2008:31(2):91–97.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Interleukin-2 Receptor Targeted Therapy of Ocular Disease of HTLV-1-associated Adult T-cell Leukemia

REFERENCES

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Interleukin-2 Receptor Targeted Therapy of Ocular Disease of HTLV-1-associated Adult T-cell Leukemia

REFERENCES

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date